

# Roberto Latini

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4181274/roberto-latini-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

360  
papers

23,714  
citations

72  
h-index

147  
g-index

388  
ext. papers

27,119  
ext. citations

7.7  
avg, IF

6.12  
L-index

#	Paper	IF	Citations
360	Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort.. <i>JACC: CardioOncology</i> , <b>2022</b> , 4, 98-109	3.8	3
359	Red blood cell fatty acid patterns from 7 countries: Focus on the Omega-3 index.. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>2022</b> , 179, 102418	2.8	0
358	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events.. <i>Annals of Medicine</i> , <b>2022</b> , 54, 1036-1046	1.5	1
357	Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 790289	5.4	0
356	Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
355	Higher levels of IgA and IgG at sepsis onset are associated with higher mortality: results from the Albumin Italian Outcome Sepsis (ALBIOS) trial. <i>Annals of Intensive Care</i> , <b>2021</b> , 11, 161	8.9	1
354	Brain Kynurenine Pathway and Functional Outcome of Rats Resuscitated From Cardiac Arrest. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021071	6	
353	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , <b>2021</b> , 21, 553	2.3	1
352	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ROMicsPin AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 684-696	9.5	23
351	Circulating pentraxin 3 in severe COVID-19 or other pulmonary sepsis. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13530	4.6	4
350	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1280-1291	6.1	5
349	Semaglutide and effective weight control. <i>Lancet, The</i> , <b>2021</b> , 397, 942-943	40	2
348	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 268-277	7.9	13
347	Esmolol during cardiopulmonary resuscitation reduces neurological injury in a porcine model of cardiac arrest. <i>Scientific Reports</i> , <b>2021</b> , 11, 10635	4.9	2
346	Albumin replacement therapy in immunocompromised patients with sepsis - Secondary analysis of the ALBIOS trial. <i>Journal of Critical Care</i> , <b>2021</b> , 63, 83-91	4	0
345	IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study. <i>BMC Cardiovascular Disorders</i> , <b>2021</b> , 21, 328	2.3	0
344	Association of high-risk coronary atherosclerosis at CCTA with clinical and circulating biomarkers: Insight from CAPIRE study. <i>Journal of Cardiovascular Computed Tomography</i> , <b>2021</b> , 15, 73-80	2.8	8

343	Effects of linagliptin on left ventricular DYSfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> , 28, 8-17	3.9	1
342	PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study. <i>Journal of Internal Medicine</i> , <b>2021</b> , 289, 179-192	10.8	11
341	Efficacy of acute administration of inhaled argon on traumatic brain injury in mice. <i>British Journal of Anaesthesia</i> , <b>2021</b> , 126, 256-264	5.4	10
340	Cardiopulmonary Resuscitation-associated Lung Edema (CRALE). A Translational Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 447-457	10.2	6
339	PMCA4 inhibition does not affect cardiac remodelling following myocardial infarction, but may reduce susceptibility to arrhythmia. <i>Scientific Reports</i> , <b>2021</b> , 11, 1518	4.9	
338	LIPCAR Is Increased in Chronic Symptomatic HF Patients. A Sub-Study of the GISSI-HF Trial. <i>Clinical Chemistry</i> , <b>2021</b> , 67, 1721-1731	5.5	0
337	Sex differences in factors associated with heart failure and diastolic left ventricular dysfunction: a cross-sectional population-based study. <i>BMC Public Health</i> , <b>2021</b> , 21, 415	4.1	2
336	Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS. <i>Critical Care</i> , <b>2021</b> , 25, 113	10.8	10
335	Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 $\mathbb{Z}$ phenotypic CAPIRE study. <i>International Journal of Cardiology</i> , <b>2021</b> , 336, 14-21	3.2	1
334	Albumin Oxidation Status in Sepsis Patients Treated With Albumin or Crystalloids. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 682877	4.6	1
333	Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure. <i>Journal of Agricultural and Food Chemistry</i> , <b>2021</b> , 69, 11236-11245	5.7	1
332	NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 653-663	7.9	1
331	Prognostic Value of a Combination of Circulating Biomarkers in Critically Ill Patients with Traumatic Brain Injury: Results from the European CReACTIVE Study. <i>Journal of Neurotrauma</i> , <b>2021</b> , 38, 2667-2676	5.4	2
330	Ventilation with the noble gas argon in an model of idiopathic pulmonary arterial hypertension in rats. <i>Medical Gas Research</i> , <b>2021</b> , 11, 124-125	2.2	1
329	Ventilation With Argon Improves Survival With Good Neurological Recovery After Prolonged Untreated Cardiac Arrest in Pigs. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e016494	6	11
328	Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 1452-1466	3.7	8
327	Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	11
326	Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial. <i>Trials</i> , <b>2020</b> , 21, 401	2.8	18

325	Early osteopontin levels predict mortality in patients with septic shock. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 78, 113-120	3.9	5
324	Cancer in chronic heart failure patients in the GISSI-HF trial. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13273	4.6	4
323	The role of resistin and myeloperoxidase in severe sepsis and septic shock: Results from the ALBIOS trial. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13333	4.6	5
322	Cardiovascular mortality and morbidity burden in successive and age pre-stratified case-control cohorts of breast cancer women. A population-based study. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 183, 177-188	4.4	
321	Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3288	3.7	6
320	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1711-1723	12.3	22
319	Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 843-851	14.6	12
318	Testing longitudinal data for prognostication in ambulatory heart failure patients with reduced ejection fraction. A proof of principle from the GISSI-HF database. <i>International Journal of Cardiology</i> , <b>2020</b> , 313, 89-96	3.2	0
317	D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis. <i>Blood Transfusion</i> , <b>2020</b> , 18, 304-311	3.6	9
316	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2078-2088	12.3	15
315	Primary pulmonary arterial hypertension: Protocol to assess comprehensively in the rat the response to pharmacologic treatments. <i>MethodsX</i> , <b>2020</b> , 7, 100771	1.9	0
314	Pentraxin-3, Troponin T, N-Terminal Pro-B-Type Natriuretic Peptide in Septic Patients. <i>Shock</i> , <b>2020</b> , 54, 675-680	3.4	1
313	Prospective Evaluation of Clinico-Pathological Predictors of Postoperative Atrial Fibrillation: An Ancillary Study From the OPERA Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2020</b> , 13, e008382	6.4	2
312	Searching for Preclinical Models of Acute Decompensated Heart Failure: a Concise Narrative Overview and a Novel Swine Model. <i>Cardiovascular Drugs and Therapy</i> , <b>2020</b> , 1	3.9	1
311	Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
310	Coronary Plaque Features on CTA Can Identify Patients at Increased Risk of Cardiovascular Events. <i>JACC: Cardiovascular Imaging</i> , <b>2020</b> , 13, 1704-1717	8.4	32
309	Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. <i>Medicina (Lithuania)</i> , <b>2019</b> , 55,	3.1	37
308	Safety of ventilation with an argon and oxygen gas mixture. <i>British Journal of Anaesthesia</i> , <b>2019</b> , 122, e31-e32	5.4	5

307	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005897	7.6	33
306	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 1751-1759	3.9	17
305	Pentraxin 3 in Cardiovascular Disease. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 823	8.4	50
304	Understanding Lactatemia in Human Sepsis. Potential Impact for Early Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 582-589	10.2	52
303	A novel echocardiographic method closely agrees with cardiac magnetic resonance in the assessment of left ventricular function in infarcted mice. <i>Scientific Reports</i> , <b>2019</b> , 9, 3580	4.9	6
302	Predicting the effects of supplemental EPA and DHA on the omega-3 index. <i>American Journal of Clinical Nutrition</i> , <b>2019</b> , 110, 1034-1040	7	42
301	Adrenomedullin, a circulating biomarker of congestion: in search of evidence. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1062-1063	12.3	2
300	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 974-984	12.3	30
299	Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor. <i>European Journal of Pharmacology</i> , <b>2019</b> , 865, 172777	5.3	7
298	Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2 Trial). Rationale, Design, and Baseline Characteristics of the Study Population. <i>Cardiovascular Drugs and Therapy</i> , <b>2019</b> , 33, 547-555	3.9	3
297	Predictive value of interatrial block for atrial fibrillation in elderly subjects enrolled in the PREDICTOR study. <i>Journal of Electrocardiology</i> , <b>2019</b> , 54, 22-27	1.4	6
296	Modes of death and prognostic outliers in chronic heart failure. <i>American Heart Journal</i> , <b>2019</b> , 208, 100-109		5
295	LUCAS Versus Manual Chest Compression During Ambulance Transport: A Hemodynamic Study in a Porcine Model of Cardiac Arrest. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e011189	6	18
294	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , <b>2019</b> , 277, 166-172	3.2	15
293	Effect of mild hypercapnia on outcome and histological injury in a porcine post cardiac arrest model. <i>Resuscitation</i> , <b>2019</b> , 135, 110-117	4	8
292	Low D-dimer levels in sepsis: Good or bad?. <i>Thrombosis Research</i> , <b>2019</b> , 174, 13-15	8.2	17
291	Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock: Data From the Albumin Italian Outcome Sepsis Study. <i>Critical Care Medicine</i> , <b>2018</b> , 46, e404-e410	1.4	18
290	Coronary sinus perforation during reducer implantation. <i>Catheterization and Cardiovascular Interventions</i> , <b>2018</b> , 91, 1291-1293	2.7	8

289	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 888-895	12.3	65
288	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. <i>Metabolism: Clinical and Experimental</i> , <b>2018</b> , 83, 205-215	12.7	20
287	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. <i>Circulation</i> , <b>2018</b> , 137, 286-297	16.7	102
286	Procalcitonin and Presepsin as Prognostic Markers After Out-of-Hospital Cardiac Arrest. <i>Shock</i> , <b>2018</b> , 50, 395-400	3.4	11
285	Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis. <i>Critical Care Medicine</i> , <b>2018</b> , 46, e221-e228		48
284	Screening for unknown atrial fibrillation in older people: a feasibility study in community pharmacies. <i>European Geriatric Medicine</i> , <b>2018</b> , 9, 113-115	3	1
283	Kit knock-in mice fail to fate-map cardiac stem cells. <i>Nature</i> , <b>2018</b> , 555, E1-E5	50.4	50
282	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. <i>European Journal of Cancer</i> , <b>2018</b> , 94, 126-137	7.5	98
281	Duration of Untreated Cardiac Arrest and Clinical Relevance of Animal Experiments: The Relationship Between the "No-Flow" Duration and the Severity of Post-Cardiac Arrest Syndrome in a Porcine Model. <i>Shock</i> , <b>2018</b> , 49, 205-212	3.4	13
280	Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 78-85	12.3	43
279	Persistence of Central Venous Oxygen Desaturation During Early Sepsis Is Associated With Higher Mortality: A Retrospective Analysis of the ALBIOS Trial. <i>Chest</i> , <b>2018</b> , 154, 1291-1300	5.3	9
278	Circulating Proenkephalin, Acute Kidney Injury, and Its Improvement in Patients with Severe Sepsis or Shock. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 1361-1369	5.5	20
277	Magic Touch <sup>®</sup> : preliminary clinical evidence with a novel sirolimus drug coated balloon. <i>Minerva Cardiology and Angiology</i> , <b>2018</b> , 66, 508-517	2.4	4
276	Reperfusion in STEMI patients: still a role for cardioprotection?. <i>Minerva Cardiology and Angiology</i> , <b>2018</b> , 66, 452-463	2.4	6
275	High- and low-affinity PEGylated hemoglobin-based oxygen carriers: Differential oxidative stress in a Guinea pig transfusion model. <i>Free Radical Biology and Medicine</i> , <b>2018</b> , 124, 299-310	7.8	10
274	The authors reply. <i>Critical Care Medicine</i> , <b>2018</b> , 46, e959-e961	1.4	
273	Fish Oil and Perioperative Bleeding. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e0045845.8		23
272	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 2309-2320	15.1	73



271	Septic shock-3 vs 2: an analysis of the ALBIOS study. <i>Critical Care</i> , <b>2018</b> , 22, 237	10.8	10
270	Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. <i>Diabetes Research and Clinical Practice</i> , <b>2018</b> , 146, 172-179	7.4	2
269	Risk stratification according to insulin type: reply. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1498	12.3	1
268	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 891-2	59.2	49
267	Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis. <i>Chest</i> , <b>2017</b> , 152, 312-320	5.3	42
266	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	27
265	Clinical and prognostic value of spot urinary creatinine in chronic heart failure-An analysis from GISSI-HF. <i>American Heart Journal</i> , <b>2017</b> , 188, 189-195	4.9	5
264	Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 256-264	7.9	21
263	Research update for articles published in EJCI in 2015. <i>European Journal of Clinical Investigation</i> , <b>2017</b> , 47, 775-788	4.6	
262	Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure. <i>Circulation Journal</i> , <b>2017</b> , 81, 1543-1546	2.9	
261	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 41-51	59.2	232
260	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	39
259	Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial. <i>European Journal of Clinical Investigation</i> , <b>2017</b> , 47, 73-83	4.6	45
258	Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 2-9	3.3	12
257	ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. <i>European Heart Journal Supplements</i> , <b>2017</b> , 19, D102-D112	1.5	9
256	Elevated plasma heparin-binding protein is associated with early death after resuscitation from cardiac arrest. <i>Critical Care</i> , <b>2016</b> , 20, 251	10.8	11
255	Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach. <i>Scientific Reports</i> , <b>2016</b> , 6, 20391	4.9	90
254	Sequential N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin Measurements During Albumin Replacement in Patients With Severe Sepsis or Septic Shock. <i>Critical Care Medicine</i> , <b>2016</b> , 44, 707-16	1.4	53

253	Coronary atherosclerosis in outlier subjects at the opposite extremes of traditional risk factors: Rationale and preliminary results of the Coronary Atherosclerosis in outlier subjects: Protective and novel Individual Risk factors Evaluation (CAPIRE) study. <i>American Heart Journal</i> , <b>2016</b> , 173, 18-26	4.9	10
252	Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 365-374	15.1	106
251	Usefulness of High-Sensitivity Cardiac Troponin T for the Identification of Outlier Patients With Diffuse Coronary Atherosclerosis and Low-Risk Factors. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1397-404	3.4	12
250	Novel biomarkers and therapies in cardiorenal syndrome. <i>Current Opinion in Pharmacology</i> , <b>2016</b> , 27, 56-61	5.1	8
249	Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook. <i>Expert Review of Cardiovascular Therapy</i> , <b>2016</b> , 14, 703-11	2.5	4
248	Interaction of Galectin-3 Concentrations with the Treatment Effects of $\beta$ -Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF. <i>Clinical Chemistry</i> , <b>2016</b> , 62, 605-16	5.5	8
247	Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 840-8	12.3	19
246	Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure trial. <i>Nutrition Research</i> , <b>2016</b> , 36, 989-994	4	23
245	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart MicroPIn AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , <b>2016</b> , 14, 181	11.4	35
244	Effects of dipeptidyl peptidase-4 (DPP-4) inhibition on angiogenesis and hypoxic injury in type 2 diabetes. <i>Life Sciences</i> , <b>2016</b> , 154, 87-95	6.8	7
243	A low plasma 1,25(OH) vitamin D/PTH (1-84) ratio predicts worsening of renal function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , <b>2016</b> , 224, 220-225	3.2	9
242	Cardiac dysfunction and circulating cardiac markers during sepsis. <i>Minerva Anestesiologica</i> , <b>2016</b> , 82, 697-710	1.9	6
241	Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkers. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 428-37	7.6	20
240	Elevations of inflammatory markers PTX3 and sST2 after resuscitation from cardiac arrest are associated with multiple organ dysfunction syndrome and early death. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2015</b> , 53, 1847-57	5.9	17
239	Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. <i>Intensive Care Medicine Experimental</i> , <b>2015</b> , 3, 44	3.7	70
238	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. <i>Circulation</i> , <b>2015</b> , 131, 1486-94; discussion 1494	16.7	66
237	Beta-Adrenoceptor Antagonists and Antianginal Drugs. <i>Side Effects of Drugs Annual</i> , <b>2015</b> , 37, 215-222	0.2	
236	Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. <i>Diabetes Research and Clinical Practice</i> , <b>2015</b> , 109, 476-84	7.4	20



235	The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk. <i>Journal of Internal Medicine</i> , <b>2015</b> , 277, 318-330	10.8	27
234	Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials." <i>Circulation</i> , <b>2015</b> , 132, e358	16.7	1
233	Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. <i>Clinica Chimica Acta</i> , <b>2015</b> , 443, 85-93	6.2	17
232	Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 12-20	14.5	89
231	Combining multiple ECG features does not improve prediction of defibrillation outcome compared to single features in a large population of out-of-hospital cardiac arrests. <i>Critical Care</i> , <b>2015</b> , 19, 425	10.8	20
230	Copeptin levels are associated with organ dysfunction and death in the intensive care unit after out-of-hospital cardiac arrest. <i>Critical Care</i> , <b>2015</b> , 19, 132	10.8	19
229	Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>PLoS ONE</i> , <b>2015</b> , 10, e0133970	3.7	17
228	Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 424-33	12.3	79
227	The effects of exogenous surfactant treatment in a murine model of two-hit lung injury. <i>Anesthesia and Analgesia</i> , <b>2015</b> , 120, 381-8	3.9	5
226	Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial. <i>Cardiovascular Drugs and Therapy</i> , <b>2015</b> , 29, 551-561	3.9	10
225	Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial. <i>European Journal of Clinical Investigation</i> , <b>2015</b> , 45, 170-8	4.6	17
224	Amplitude spectrum area to guide defibrillation: a validation on 1617 patients with ventricular fibrillation. <i>Circulation</i> , <b>2015</b> , 131, 478-87	16.7	52
223	The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure. <i>Journal of Internal Medicine</i> , <b>2014</b> , 275, 621-30	10.8	37
222	The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 1249-51	3.2	3
221	Relationship between post-cardiac arrest myocardial oxidative stress and myocardial dysfunction in the rat. <i>Journal of Biomedical Science</i> , <b>2014</b> , 21, 70	13.3	15
220	Effect of prone positioning during mechanical ventilation on mortality among patients with acute respiratory distress syndrome: a systematic review and meta-analysis. <i>Cmaj</i> , <b>2014</b> , 186, E381-90	3.5	136
219	Albumin replacement in patients with severe sepsis or septic shock. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1412-21	59.2	677
218	Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest. <i>Heart Rhythm</i> , <b>2014</b> , 11, 1641-7	6.7	7

217	Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. <i>Critical Care</i> , <b>2014</b> , 18, R6	10.8	132
216	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2014</b> , 35, 351-357	0.2	1
215	Adrenoceptor Antagonists and Antianginal Drugs. <i>Side Effects of Drugs Annual</i> , <b>2014</b> , 267-273	0.2	
214	Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. <i>Cardiovascular Research</i> , <b>2014</b> , 104, 37-48	9.9	35
213	Postresuscitation treatment with argon improves early neurological recovery in a porcine model of cardiac arrest. <i>Shock</i> , <b>2014</b> , 41, 72-8	3.4	37
212	Early activation of the kynurenine pathway predicts early death and long-term outcome in patients resuscitated from out-of-hospital cardiac arrest. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3,	6	33
211	Heart OmicsPin AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , <b>2014</b> , 28, 349-59	1.5	16
210	Circulating Cardiac Biomarkers and Outcome <b>2014</b> , 211-217		
209	A combination of untargeted and targeted metabolomics approaches unveils changes in the kynurenine pathway following cardiopulmonary resuscitation. <i>Metabolomics</i> , <b>2013</b> , 9, 839-852	4.7	10
208	Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial. <i>BMC Cardiovascular Disorders</i> , <b>2013</b> , 13, 28	2.3	33
207	Early kynurenine pathway activation following cardiac arrest in rats, pigs, and humans. <i>Resuscitation</i> , <b>2013</b> , 84, 1604-10	4	28
206	Telomere/telomerase system impairment in circulating angiogenic cells of geriatric patients with heart failure. <i>International Journal of Cardiology</i> , <b>2013</b> , 164, 99-105	3.2	15
205	Tubular damage and worsening renal function in chronic heart failure. <i>JACC: Heart Failure</i> , <b>2013</b> , 1, 417-24	7.9	73
204	CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 747-55	12.3	9
203	Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure. <i>Pharmacological Research</i> , <b>2013</b> , 73, 35-43	10.2	21
202	Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 935-40.e1	4.9	27
201	n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1289-95	12.3	25
200	n-3PUFA and Holter-derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy. <i>Heart Rhythm</i> , <b>2013</b> , 10, 226-32	6.7	19

199	Fish oil and post-operative atrial fibrillation: a meta-analysis of randomized controlled trials. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 2194-6	15.1	49
198	Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. <i>American Heart Journal</i> , <b>2013</b> , 165, 208-15	4.9	51
197	Myocardial infarction: cardioprotection by erythropoietin. <i>Methods in Molecular Biology</i> , <b>2013</b> , 982, 265-302	3.7	6
196	An opto-structural method to estimate the stress-strain field induced by cell contraction on substrates of controlled stiffness in vitro. <i>Journal of Applied Biomaterials and Functional Materials</i> , <b>2013</b> , 11, e143-50	1.8	2
195	Cardiovascular biomarkers, cardiac dysfunction, and outcomes in patients with type 2 diabetes: a prospective, multicenter study. <i>Diabetes Care</i> , <b>2013</b> , 36, e137-8	14.6	3
194	Significance of measurable cardiac troponin by high-sensitivity assays in patients with chronic stable heart failure. <i>Coronary Artery Disease</i> , <b>2013</b> , 24, 716-9	1.4	5
193	Natriuretic peptides in acute chest pain and acute coronary syndrome: from pathophysiology to clinical and prognostic applications. <i>Coronary Artery Disease</i> , <b>2013</b> , 24, 33-9	1.4	2
192	Plasma phospholipid omega-3 fatty acids and incidence of postoperative atrial fibrillation in the OPERA trial. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000397	6	23
191	High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals. <i>Journal of Internal Medicine</i> , <b>2013</b> , 273, 306-17	10.8	22
190	Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1236-44	12.3	40
189	Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from PREDICTOR, a population based-study in central Italy. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1102-12	12.3	15
188	Unilateral acid aspiration augments the effects of ventilator lung injury in the contralateral lung. <i>Anesthesiology</i> , <b>2013</b> , 119, 642-51	4.3	11
187	Reduction In body weight is an independent risk factor for mortality in chronic heart failure. Insights from GISSI-HF and Val-HeFT trials. <i>European Heart Journal</i> , <b>2013</b> , 34, P1526-P1526	9.5	
186	1050. <i>Critical Care Medicine</i> , <b>2013</b> , 41, A264	1.4	1
185	NT-proBNP: A Guide to Improve the Management of Patients with Heart Failure. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , <b>2013</b> , 24, 78-84	2.4	4
184	Systematic review and meta-analysis: renin-Angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope. <i>Cardiovascular Drugs and Therapy</i> , <b>2012</b> , 26, 47-54	3.9	23
183	Hydroxytyrosol attenuates peripheral neuropathy in streptozotocin-induced diabetes in rats. <i>Journal of Agricultural and Food Chemistry</i> , <b>2012</b> , 60, 5859-65	5.7	34
182	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2012</b> , 34, 303-310	0.2	

181	Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , <b>2012</b> , 26, 131-143	3.9	9
180	Pentraxin-3 predicts functional recovery and 1-year major adverse cardiovascular events after rehabilitation of cardiac surgery patients. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , <b>2012</b> , 32, 17-24	3.6	13
179	Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 2001-11	27.4	168
178	Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 718-29	12.3	71
177	Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 992-9	12.3	72
176	Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. <i>Circulation</i> , <b>2012</b> , 125, 280-8	16.7	177
175	L-selectin and SDF-1 enhance the migration of mouse and human cardiac mesoangioblasts. <i>Cell Death and Differentiation</i> , <b>2012</b> , 19, 345-55	12.7	19
174	Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in macrophages. <i>Journal of Immunology</i> , <b>2012</b> , 188, 4081-92	5.3	53
173	A multicentre, randomised, open-label, controlled trial evaluating equivalence of inhalational and intravenous anaesthesia during elective craniotomy. <i>European Journal of Anaesthesiology</i> , <b>2012</b> , 29, 371-3	3.3	59
172	Pentraxins and Atherosclerosis <b>2012</b> , 219-237		
171	Ex vivo-expanded bone marrow CD34(+) for acute myocardial infarction treatment: in vitro and in vivo studies. <i>Cytotherapy</i> , <b>2011</b> , 13, 1140-52	4.8	7
170	Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. <i>American Heart Journal</i> , <b>2011</b> , 161, 838-43	4.9	47
169	The Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design. <i>American Heart Journal</i> , <b>2011</b> , 162, 56-63.e3	4.9	23
168	Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. <i>American Heart Journal</i> , <b>2011</b> , 162, 382-9	4.9	24
167	Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2011</b> , 21, 783-91	4.5	19
166	The effect of a single bolus of exogenous surfactant on lung compliance persists until two weeks after treatment in a model of acid aspiration pneumonitis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2011</b> , 24, 141-6	3.5	4
165	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2011</b> , 33, 397-406	0.2	
164	Histone deacetylase inhibition enhances self renewal and cardioprotection by human cord blood-derived CD34 cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e22158	3.7	19

163	Role of renin-angiotensin system inhibitors in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , <b>2011</b> , 12, 374; author reply 375	1.9	
162	Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 1994-2003	1.9	15
161	Adiponectin in chronic heart failure: influence of diabetes and genetic variants. <i>European Journal of Clinical Investigation</i> , <b>2011</b> , 41, 1330-8	4.6	13
160	Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. <i>Journal of Internal Medicine</i> , <b>2011</b> , 269, 160-71	10.8	55
159	Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertension. <i>European Journal of Pharmacology</i> , <b>2011</b> , 667, 287-91	5.3	9
158	Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. <i>Cardiovascular Drugs and Therapy</i> , <b>2011</b> , 25, 315-21	3.9	5
157	A mouse model for spatial and temporal expression of HGF in the heart. <i>Transgenic Research</i> , <b>2011</b> , 20, 1203-16	3.3	8
156	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 755-64	12.3	15
155	Pentraxins and atherosclerosis: the role of PTX3. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 38-46	3.3	41
154	Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 746-54	12.3	25
153	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2011</b> , 18, 415-23		25
152	Clinical outcome of renal tubular damage in chronic heart failure. <i>European Heart Journal</i> , <b>2011</b> , 32, 2705-12	12.3	149
151	Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy. <i>Circulation: Cardiovascular Imaging</i> , <b>2011</b> , 4, 721-8	3.9	7
150	Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial. <i>Circulation: Heart Failure</i> , <b>2010</b> , 3, 65-72	7.6	81
149	Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 549-56	12.3	47
148	Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1345-53	12.3	62
147	The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 338-47	12.3	116
146	Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , <b>2010</b> , 16, 964-70	3.3	48

145	Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. <i>American Heart Journal</i> , <b>2010</b> , 159, 857-63	4.9	18
144	Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. <i>American Heart Journal</i> , <b>2010</b> , 160, 286-93	4.9	52
143	Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. <i>Heart</i> , <b>2010</b> , 96, 1909-14	5.4	25
142	Elevated plasma and alveolar levels of soluble receptor for advanced glycation endproducts are associated with severity of lung dysfunction in ARDS patients. <i>Tohoku Journal of Experimental Medicine</i> , <b>2010</b> , 222, 105-12	2.4	27
141	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2010</b> , 363-369	0.2	
140	Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. <i>Intensive Care Medicine</i> , <b>2010</b> , 36, 585-99	14.5	377
139	An update on cardiac troponins as circulating biomarkers in heart failure. <i>Current Heart Failure Reports</i> , <b>2010</b> , 7, 15-21	2.8	13
138	Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis. <i>EuroIntervention</i> , <b>2010</b> , 6, 527-36	3.1	27
137	Valsartan for prevention of recurrent atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1606-17	6.7	367
136	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 119-29	12.3	248
135	Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 3356-72	15.9	145
134	Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 1977-84	27.4	324
133	Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. <i>European Heart Journal</i> , <b>2009</b> , 30, 2327-36	9.5	84
132	Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 68-76	12.3	78
131	Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and differentiation potency. <i>Cardiovascular Research</i> , <b>2009</b> , 83, 707-16	9.9	41
130	Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. <i>Heart</i> , <b>2009</b> , 95, 1920-4	5.1	23
129	Anaesthesiological strategies in elective craniotomy: randomized, equivalence, open trial--the NeuroMorfeo trial. <i>Trials</i> , <b>2009</b> , 10, 19	2.8	13
128	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. <i>Expert Review of Cardiovascular Therapy</i> , <b>2009</b> , 7, 735-48	2.5	32



127	Levels of circulating pro-angiogenic cells predict cardiovascular outcomes in patients with chronic heart failure. <i>Journal of Cardiac Failure</i> , <b>2009</b> , 15, 747-55	3.3	8
126	Biomarkers of myocyte injury in heart failure. <i>Heart Failure Clinics</i> , <b>2009</b> , 5, 529-36	3.3	2
125	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2009</b> , 31, 339-343	0.2	
124	Disruption of the Ang II type 1 receptor promotes longevity in mice. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 524-30	15.9	374
123	Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. <i>Cell Death and Differentiation</i> , <b>2008</b> , 15, 1417-28	12.7	87
122	Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 56-60	3	34
121	Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 749-54	3	58
120	Valor pronóstico de las troponinas circulantes en la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , <b>2008</b> , 61, 667-669	1.5	1
119	Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 997-1003	15.1	252
118	Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial. <i>American Heart Journal</i> , <b>2008</b> , 155, 388-94	4.9	21
117	Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2008</b> , 372, 1223-30	40	998
116	Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2008</b> , 372, 1231-9	40	767
115	Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. <i>Circulation</i> , <b>2008</b> , 117, 1055-64	16.7	270
114	Prothrombotic gene expression profile in vascular smooth muscle cells of human saphenous vein, but not internal mammary artery. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 705-10	9.4	21
113	Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. <i>Circulation: Heart Failure</i> , <b>2008</b> , 1, 17-24	7.6	292
112	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2008</b> , 30, 223-230	0.2	2
111	Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?. <i>Heart Failure Reviews</i> , <b>2008</b> , 13, 415-23	5	37
110	Lung injury and recovery in a murine model of unilateral acid aspiration: functional, biochemical, and morphologic characterization. <i>Anesthesiology</i> , <b>2008</b> , 108, 1037-46	4.3	54

109	Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. <i>Circulation</i> , <b>2007</b> , 116, 1242-9	16.7	533
108	Effects of exercise training on endothelial progenitor cells in patients with chronic heart failure. <i>Journal of Cardiac Failure</i> , <b>2007</b> , 13, 701-8	3.3	84
107	A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 129-35	12.3	38
106	Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 397-402	12.3	59
105	18 Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2007</b> , 194-201	0.2	
104	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). <i>Journal of Cardiovascular Medicine</i> , <b>2007</b> , 8, 683-91	1.9	15
103	Incorporation and washout of n-3 polyunsaturated fatty acids after diet supplementation in clinical studies. <i>Journal of Cardiovascular Medicine</i> , <b>2007</b> , 8 Suppl 1, S4-10	1.9	19
102	Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. <i>Journal of Cardiac Failure</i> , <b>2007</b> , 13, 797-804	3.3	66
101	Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats. <i>Life Sciences</i> , <b>2007</b> , 81, 951-9	6.8	20
100	Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. <i>International Journal of Cardiology</i> , <b>2007</b> , 119, 48-53	3.2	57
99	Neurohormonal modulation in heart failure of ischemic etiology: correlates with left ventricular remodeling. <i>Current Heart Failure Reports</i> , <b>2006</b> , 3, 157-63	2.8	4
98	Murine models of myocardial and limb ischemia: diagnostic end-points and relevance to clinical problems. <i>Vascular Pharmacology</i> , <b>2006</b> , 45, 281-301	5.9	41
97	The long pentraxin PTX3 in vascular pathology. <i>Vascular Pharmacology</i> , <b>2006</b> , 45, 326-30	5.9	92
96	Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT. <i>European Journal of Heart Failure</i> , <b>2006</b> , 8, 502-8	12.3	10
95	Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. <i>Clinical Chemistry</i> , <b>2006</b> , 52, 1528-38	5.5	270
94	The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , <b>2006</b> , 12, 375-80	3.3	54
93	Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. <i>American Journal of Medicine</i> , <b>2006</b> , 119, 70.e23-30	2.4	82
92	Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. <i>Life Sciences</i> , <b>2006</b> , 79, 121-9	6.8	83

91	Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. <i>Journal of Cardiovascular Medicine</i> , <b>2006</b> , 7, 29-38	1.9	37
90	Increased erythropoietin production after myocardial infarction in mice. <i>Heart</i> , <b>2006</b> , 92, 838-9	5.1	9
89	A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 2046-51	11.5	183
88	Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). <i>American Heart Journal</i> , <b>2005</b> , 149, 548-57	4.9	341
87	Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 91-8	3.3	100
86	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2005</b> , 217-222	0.2	
85	Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 698-704	3	58
84	StarC II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. <i>Catheterization and Cardiovascular Interventions</i> , <b>2005</b> , 64, 375-82	2.7	24
83	Cardiac Fibrosis and Aging <b>2005</b> , 97-103		3
82	Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. <i>Circulation</i> , <b>2005</b> , 112, 1121-7	16.7	195
81	C-reactive protein in heart failure: prognostic value and the effect of valsartan. <i>Circulation</i> , <b>2005</b> , 112, 1428-34	16.7	329
80	Junctional adhesion molecule-A-deficient polymorphonuclear cells show reduced diapedesis in peritonitis and heart ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 10634-9	11.5	98
79	Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: a comparison with bone marrow progenitors, fibroblasts, and endothelial cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2005</b> , 25, 692-7	9.4	78
78	Recommendations for the clinical use of cardiac natriuretic peptides. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , <b>2005</b> , 6, 430-46		4
77	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2004</b> , 203-208	0.2	
76	Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. <i>Circulation</i> , <b>2004</b> , 110, 2349-54	16.7	358
75	The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. <i>European Heart Journal</i> , <b>2004</b> , 25, 292-9	9.5	262
74	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. <i>European Journal of Heart Failure</i> , <b>2004</b> , 6, 635-41	12.3	180

73	RAAS inhibitors in the cardiovascular continuum: what is still missing?. <i>Cardiovascular Drugs and Therapy</i> , <b>2004</b> , 18, 311-20	3.9	2
72	Valsartan for the treatment of heart failure. <i>Expert Opinion on Pharmacotherapy</i> , <b>2004</b> , 5, 181-93	4	4
71	Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 14907-12	11.5	545
70	Doppler-derived mitral deceleration time as a strong prognostic marker of left ventricular remodeling and survival after acute myocardial infarction: results of the GISSI-3 echo substudy. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 1646-53	15.1	117
69	Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 2022-7	15.1	171
68	Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. <i>Journal of Cardiac Failure</i> , <b>2004</b> , 10, 433-41	3.3	18
67	Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2004</b> , 37, 959-68	5.8	170
66	The long pentraxin PTX3: from innate immunity to ischemic heart disorders. <i>International Congress Series</i> , <b>2004</b> , 1262, 63-66		
65	Myocardial infarction: animal models. <i>Methods in Molecular Medicine</i> , <b>2004</b> , 98, 217-26		18
64	Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. <i>Circulation</i> , <b>2003</b> , 108, 1306-9	16.7	85
63	In vivo cardioprotection by N-acetylcysteine and isosorbide 5-mononitrate in a rat model of ischemia-reperfusion. <i>Cardiovascular Drugs and Therapy</i> , <b>2003</b> , 17, 199-208	3.9	15
62	Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAM1) trial. <i>American Heart Journal</i> , <b>2003</b> , 146, 133	4.9	6
61	Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 4802-6	11.5	511
60	Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). <i>Circulation</i> , <b>2003</b> , 107, 1278-83	16.7	698
59	Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2002</b> , 40, 761-3	5.9	57
58	Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. <i>European Heart Journal</i> , <b>2002</b> , 23, 536-42	9.5	20
57	Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). <i>Circulation</i> , <b>2002</b> , 106, 2454-8	16.7	259
56	Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2002</b> , 34, 1655-65	5.8	59

55	Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 970-5	15.1	196
54	Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 1414-21	15.1	271
53	Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. <i>Journal of Cardiac Failure</i> , <b>2002</b> , 8, 288-99	3.3	39
52	The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years?. <i>Blood Pressure</i> , <b>2002</b> , 11, 328-38	1.7	9
51	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. <i>Lancet, The</i> , <b>2002</b> , 360, 1037-43	4.0	188
50	Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT). <i>Journal of the American Society of Echocardiography</i> , <b>2002</b> , 15, 293-301	5.8	24
49	CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload. <i>Cardiovascular Drugs and Therapy</i> , <b>2001</b> , 15, 131-8	3.9	14
48	Cardiac protection by pharmacological modulation of inflammation. <i>Expert Opinion on Investigational Drugs</i> , <b>2001</b> , 10, 1913-24	5.9	2
47	What does the future hold for BNP in cardiology?. <i>British Heart Journal</i> , <b>2001</b> , 86, 601-2		5
46	Effect of prone positioning on the survival of patients with acute respiratory failure. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 568-73	59.2	894
45	Adjuvant Radiochemotherapy in High-Risk Rectal Cancer Results of a Prospective Non-Randomized Study. <i>Tumori</i> , <b>2001</b> , 87, 239-247	1.7	9
44	Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. <i>Laboratory Investigation</i> , <b>2000</b> , 80, 513-27	5.9	262
43	Left ventricular response to beta-adrenergic stimulation in aging rats. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2000</b> , 55, B35-41; discussion B42-3	6.4	11
42	Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. <i>European Heart Journal</i> , <b>2000</b> , 21, 1368-75	9.5	182
41	Up-regulation of AT(1) and AT(2) receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell death. <i>American Journal of Pathology</i> , <b>2000</b> , 156, 1663-72	5.8	59
40	PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. <i>Circulation</i> , <b>2000</b> , 102, 636-41	16.7	345
39	Use of ACE-inhibitors lowered the rate of mortality, reinfarction, and hospital readmission in patients with heart failure or left ventricular dysfunction. <i>Evidence-based Cardiovascular Medicine</i> , <b>2000</b> , 4, 74		
38	Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 35, 1801-7	15.1	129

37	The Heart in Diabetes: Results of Trials <b>2000</b> , 55-65		
36	Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. <i>Circulation</i> , <b>1999</b> , 100, 1056-64	16.7	735
35	How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI. <i>American Heart Journal</i> , <b>1999</b> , 138, S183-7	4.9	8
34	Effects of a DA2/alpha2 agonist and a beta1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 34, 321-6	3.1	18
33	Age-dependent expression of fibrosis-related genes and collagen deposition in the rat myocardium. <i>Mechanisms of Ageing and Development</i> , <b>1998</b> , 101, 57-72	5.6	50
32	Within-patient variability of hormone and cytokine concentrations in heart failure. <i>Pharmacological Research</i> , <b>1998</b> , 37, 213-7	10.2	25
31	Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes. <i>Pharmacological Research</i> , <b>1998</b> , 37, 233-40	10.2	25
30	Remodelling of cardiac extracellular matrix during beta-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. <i>Journal of Molecular and Cellular Cardiology</i> , <b>1998</b> , 30, 1505-14	5.8	49
29	Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 31, 601-8	3.1	27
28	The Heart in Diabetes: Results of Trials <b>1998</b> , 51-60		
27	Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine? GISSI experience, 1984-1993. The Gruppo Italiano di Studio sulla Sopravvivenza nell'Infarto Miocardico (GISSI) Investigators. <i>European Heart Journal</i> , <b>1997</b> , 18, 1447-56	9.5	19
26	Ventilation in the prone position. The Prone-Supine Study Collaborative Group. <i>Lancet</i> , <b>1997</b> , 350, 815	4.0	16
25	Treatment of acute myocardial infarction today. <i>American Heart Journal</i> , <b>1997</b> , 134, S9-14	4.9	2
24	Analytical Agreement and Clinical Correlates of Plasma Brain Natriuretic Peptide Measured by Three Immunoassays in Patients with Heart Failure. <i>Clinical Chemistry</i> , <b>1997</b> , 43, 2439-2440	5.5	6
23	Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. <i>Journal of Diabetes and Its Complications</i> , <b>1997</b> , 11, 131-6	3.2	13
22	Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. <i>Circulation</i> , <b>1997</b> , 96, 4239-45	16.7	149
21	Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. <i>Canadian Journal of Cardiology</i> , <b>1997</b> , 13, 1166-74	3.8	33
20	Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice. <i>European Journal of Pharmacology</i> , <b>1996</b> , 317, 369-76	5.3	14



19	The prognostic value of predischARGE quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. <i>European Heart Journal</i> , <b>1996</b> , 17, 1646-56	9.5	89
18	Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? GISSI-3 Investigators. <i>Cardiology</i> , <b>1996</b> , 87 Suppl 1, 16-22	1.6	3
17	Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI experience). <i>American Journal of Cardiology</i> , <b>1996</b> , 78, 153-7	3	5
16	Idrapril, A Novel ACE Inhibitor. <i>Cardiovascular Drug Reviews</i> , <b>1996</b> , 14, 351-363		
15	Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. <i>Circulation</i> , <b>1996</b> , 94, 432-6	16.7	167
14	Effects of a new angiotensin-converting enzyme inhibitor (idrapril) in rats with left ventricular dysfunction after myocardial infarction. <i>Journal of Cardiovascular Pharmacology</i> , <b>1996</b> , 27, 347-54	3.1	5
13	A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1025-32	59.2	1241
12	ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. <i>Circulation</i> , <b>1995</b> , 92, 3132-7	16.7	140
11	Cytokines in Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , <b>1994</b> , 23, 1	3.1	127
10	Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. <i>Journal of Cardiovascular Pharmacology</i> , <b>1994</b> , 23, 1-6	3.1	26
9	Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. <i>Journal of the American College of Cardiology</i> , <b>1993</b> , 22, 1788-94	15.1	206
8	Ventricular arrhythmias and four-year mortality in haemodialysis patients. Gruppo Emodialisi e Patologie Cardiovascolari. <i>Lancet, The</i> , <b>1992</b> , 339, 212-3	40	61
7	Antiinflammatory action of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy. <i>European Journal of Pharmacology</i> , <b>1989</b> , 159, 257-64	5.3	13
6	Demonstration of a different sensitivity to epinephrine in isolated and in vivo hearts. <i>European Journal of Pharmacology</i> , <b>1988</b> , 156, 87-94	5.3	3
5	Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. <i>Circulation</i> , <b>1985</b> , 72, 1185-93	16.7	96
4	Inhibition of human platelet thromboxane generation by aspirin in the absence of measurable drug levels in peripheral blood. <i>Biochemical Pharmacology</i> , <b>1985</b> , 34, 1839-41	6	19
3	Simple estimate of the true right to left shunt (Qs/Qt) at maintenance FIO2 by sulphur hexafluoride retention. <i>Intensive Care Medicine</i> , <b>1982</b> , 8, 283-6	14.5	19
2	Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition. <i>Journal of Clinical Investigation</i> , <b>1981</b> , 68, 1108-12	15.9	51

1 Pentraxins in Vascular Pathology: The Role of PTX3 137-154